Amsterdam UMC spinout developing a precision immunotherapy platform that uses patented single-domain antibody carriers to selectively deliver antigens or immunomodulators to antigen-presenting cells, aiming to generate targeted immune responses against cancer and other immune-mediated diseases
Amsterdam UMC spinout developing a precision immunotherapy platform that uses patented single-domain antibody carriers to selectively deliver antigens or immunomodulators to antigen-presenting cells, aiming to generate targeted immune responses against cancer and other immune-mediated diseases. The company is advancing preclinical development and seeking partnerships and investment.